Researchers from Phio Pharmaceuticals Corp. presented preclinical data for PH-109, a novel self-delivering RNAi targeting connective tissue growth factor (CTGF), which was originally developed and assessed in early clinical trials as potential treatment of dermal hypertrophic scarring and subretinal fibrosis. The current study evaluated PH-109 in a mouse model of metastatic breast cancer.